A Faegre Drinker team led by corporate partners Matt Stamski and Brandon Mason advised medical device company Boston Scientific in its acquisition of Preventice Solutions, Inc., a privately held company, which offers a full portfolio of mobile cardiac health solutions and services, ranging from ambulatory cardiac monitors — including short and long-term Holter monitors — to cardiac event monitors and mobile cardiac telemetry. The acquisition consists of an upfront cash payment of $925 million, and up to an additional $300 million in a potential commercial milestone payment.
Additional advisors from the firm included labor and employment partner Dan Prokott and counsel Rhiannon Beckendorf; health care partner Steve Lokensgard and associate Alex Eschenroeder; FDA-regulated products partner Amy Judge-Prein and counsel Ted Lis; privacy, cybersecurity and data strategy partners Doriann Cain and Paul Luehr; intellectual property partners Jason Kraus and Rob Leonard; benefits and executive compensation partner Gayle Skolnik and associate Mark Rosenfeld; tax partner Charles Bybee; litigation partner Elsa Bullard; mergers and acquisitions insurance partner Kate Sherburne; and real estate partner Treasa Burke and associate Zachary Mahone.
Boston Scientific transforms lives through innovative medical solutions that improve the health of patients around the world. As a global medical technology leader for more than 40 years, the company advances science for life by providing a broad range of high performance solutions that address unmet patient needs and reduce the cost of healthcare.
Read Boston Scientific’s press release for more information on the deal.